Is the business good?
How good a business is KNSA?
Kiniksa Pharmaceuticals International, plc earns 54% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
54%
Return on invested capital · cost of capital 9.0% · 45 points above what the capital costs: growth creates value
- Operating margin
- 12%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Cash conversion
- 2.25×
Cash conversion · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- +8.2%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2021 | −406% |
| FY2022 | 4.4% |
| FY2023 | −9.3% |
| FY2024 | −11% |
| FY2025 | 11% |
Details›
- Gross margin12 months to Q1 2026
- 89%
- Operating margin12 months to Q1 2026
- 12%
- Net margin12 months to Q1 2026
- 9.7%
- Free cash flow margin
- 22%
- R&D as % of revenue
- 14%
- Revenue, trailing twelve months
- $754M
- Free cash flow, trailing twelve months
- $164M
- Net income, trailing twelve months
- $73M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 54%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #18 of 28 by Smart Score